HUE029880T2 - Súlyos szívesemények rizikójának elõrejelzése - Google Patents

Súlyos szívesemények rizikójának elõrejelzése Download PDF

Info

Publication number
HUE029880T2
HUE029880T2 HUE14177846A HUE14177846A HUE029880T2 HU E029880 T2 HUE029880 T2 HU E029880T2 HU E14177846 A HUE14177846 A HU E14177846A HU E14177846 A HUE14177846 A HU E14177846A HU E029880 T2 HUE029880 T2 HU E029880T2
Authority
HU
Hungary
Prior art keywords
subject
mac mac
time
probnp
mace
Prior art date
Application number
HUE14177846A
Other languages
English (en)
Inventor
James V Snider
Eugene R Heyman
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Publication of HUE029880T2 publication Critical patent/HUE029880T2/hu

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Electrotherapy Devices (AREA)

Claims (7)

  1. Szabadalmi Igéayptaek E'P*ts alany állapotának: értékelésé^ $3 íj# során.. à? eljárás t$jhd:ma«za;; meghatározunk dsô MACE {maint %émm· sáídiá© évém»· süîyos sxivesenrény) opíkóértékíít '(MACERS.) áa aisuy száméra, amely U-galább egy; yddkaéb Growth Si<Muiáte»$bi$tóe^6$ Géb« (növekedési; stinmlaoioexitrpsSzak gén) 2 (ΒΤ2| alanyba*» második: sgáííijési'sk második: Möken: (EX2 Ti j: oldható ÍSX2 alanyban! első sssiRgéhsx első időben (ST2 TO} visgonyireti arányán dftjpill hozzáadva alanyba«! $d®rffiíMlis hgytipnsu náEiiirotíte :jté;ptiíj (EiT^proBAÍf): színijének snlyogoit ierinésze» logaritmusát másodikidSbon (NP Ti) a kőveikezöklpisiszötint el so MACFiRS * ÍST2 TI /SÍT 1 ö) + dniNP Ti), ahol ö súlyoző iétyymÓl meghatározunk második M ACTES··!: alany számára amely legalább restben az alanyban! oldható ST2 aMMiófiok: harmadik időben (ST2 T2} okihstó ST2 m. alanyban!'· első szintjéhez dise kidben (Sí 2 TO) viszonyiiöit arányén alapul,, hözslsdya NT^nABhiP alanyban* ^isijtek sülvöKott temsészetes lögaAMÄät .32 alanyba» a harmadik időben. (NP T2}:a :köv«ike2ö képlet:szesifít:: m&amp;cMk MACEES ~ (ST2 T2/SÎ2 TO) + áfa{$P T2), ahol a súlyozó tényépő; ahol a második ;MACE&amp;S az diso blMIERSmí: való összeImzmiliíasxí joízi bogy m alany állapota hanyatlik, javtd, vagy nem változik.
  2. 2, Az 1. igé&amp;ypoöt szórttal alphas, ahol második MACERS esőkken, dsszeMsobíkva az első MACERS-d jelzi, hogy az alany állapota javul
  3. 3, Az I, Igénypo:« szerinti eljárás. ahol második M ACTE S növekszik, összehasonlítva az elad MAC EPS-el jelzi, hogy az alany áiiapdiá hasiyatMk,
  4. 4, Az !. igéayf odt szöÉn íi élj árás, ;ákű az eljárás iaOsimazííá: oldható ST2 älasyOilhi: első szintiének mégkapáíiát az dis# időpontban, .hogy megsnúátozztik ST2 TO-t; oldható ST2 a lanyhán: másod tk szintiének insgkápását a niásodík időpontban. hogy meghatározzuk $12 Ti··;: oldható ST2 alanyba*» hamsad jk szfeprsek megkapását a harmadik időpő»íl>Z», hogy ffieghtstározsnk ST212- t: MT~prdBíkF az aiáhybáhi a második időpontban, hogy anegbatdtozmtk dtp 11 et: és NT-profi NP az aliötyhani Minijének megkapását a háfiMáik idöpooiha«. hogy megHaisroxzuk;: 1PT2A. 5, A» 1, igénypont szerinti eljárás, ahol a súlyozó tényező uiköfüiheliil 0,33. ó- Az i. igénypont széfinő eljárás, 4hói m első: időpont i -? napon beiül van a íisitnptőmzk ieiiépfe után az alanyban.
  5. 7. Az. I. igénypont szonnti eljárás, aho; második klümmi 2· 14 maxin belül van első időpont után. §, Az C igénypont: szerinti eljárás, ahui az alanynak iiiagntrsznzáí; sziveíégteieníiége van,
  6. 9. Az i. igénypont szerinti eljárás, ahol az alany BMl-je 25-29. í0. /V.··: í. igénypont szerinti eljárás, ahol a?, alany lïMi-je y 20. I !. M. i. igénypont szerinti eljárás, ahol alany v$ss«tégt€>taségheft szenved.
  7. 12. Az I. igénypont szerinti eljárás, ahol. a suinta sz#ooioi, vési vagy plazmát tartalmaz.
HUE14177846A 2008-04-18 2009-04-17 Súlyos szívesemények rizikójának elõrejelzése HUE029880T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4615808P 2008-04-18 2008-04-18

Publications (1)

Publication Number Publication Date
HUE029880T2 true HUE029880T2 (hu) 2017-04-28

Family

ID=41199760

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE16166093A HUE039963T2 (hu) 2008-04-18 2009-04-17 Súlyos káros szívesemények rizikójának elõrejelzése
HUE14177846A HUE029880T2 (hu) 2008-04-18 2009-04-17 Súlyos szívesemények rizikójának elõrejelzése

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE16166093A HUE039963T2 (hu) 2008-04-18 2009-04-17 Súlyos káros szívesemények rizikójának elõrejelzése

Country Status (14)

Country Link
US (5) US8090562B2 (hu)
EP (5) EP2827152B1 (hu)
JP (6) JP5526122B2 (hu)
AU (3) AU2009236109B2 (hu)
CA (1) CA2720674A1 (hu)
DK (4) DK2827152T3 (hu)
ES (4) ES2525029T3 (hu)
HK (3) HK1152750A1 (hu)
HR (2) HRP20131100T1 (hu)
HU (2) HUE039963T2 (hu)
PL (4) PL3093663T3 (hu)
PT (4) PT3093663T (hu)
SI (4) SI2660599T1 (hu)
WO (1) WO2009129454A2 (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
EP3072978B1 (en) 2002-05-09 2018-07-11 The Brigham and Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker
ES2351623T3 (es) 2006-04-24 2011-02-08 Critical Care Diagnostics, Inc. Predicción de la mortalidad y detección de una enfermedad grave.
US20090305265A1 (en) * 2006-04-27 2009-12-10 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
PT2021796E (pt) 2006-05-01 2012-04-19 Critical Care Diagnostics Inc Diagnóstico de doença cardiovascular
HUE025058T2 (hu) * 2006-05-02 2016-01-28 Critical Care Diagnostics Inc Pulmonáris és cardiovasculáris betegség differenciáldiagnózisa
US9968266B2 (en) 2006-12-27 2018-05-15 Cardiac Pacemakers, Inc. Risk stratification based heart failure detection algorithm
DK2827152T3 (en) 2008-04-18 2016-09-12 Critical Care Diagnostics Inc PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS
JP5711131B2 (ja) * 2008-10-07 2015-04-30 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 最初の有害事象の予測のためのバイオマーカー
US9561006B2 (en) * 2008-10-15 2017-02-07 The United States Of America As Represented By The Secretary Of The Navy Bayesian modeling of pre-transplant variables accurately predicts kidney graft survival
US8417541B1 (en) * 2009-08-27 2013-04-09 Cerner Innovation, Inc. Multi-stage model for predicting probabilities of mortality in adult critically ill patients
US20220139561A1 (en) * 2009-09-25 2022-05-05 Volcano Corporation Device and Method for Determining the Likelihood of a Patient Having a Clinical Event or a Clinically Silent Event Based on Ascertained Physiological Parameters
BR112012025728B1 (pt) 2010-04-09 2022-01-11 Critical Care Diagnostics, Inc Anticorpos isolados ou fragmentos que se liga a st2 humano solúvel, hibridoma, kit, bem como métodos para quantificação de um nível de st2 solúvel humano em uma amostra de um indivíduo, e para a predição do risco de morte dentro de um ano em um indivíduo
US10943676B2 (en) 2010-06-08 2021-03-09 Cerner Innovation, Inc. Healthcare information technology system for predicting or preventing readmissions
EP3605104B1 (en) 2011-03-17 2021-09-15 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
WO2013012945A1 (en) 2011-07-18 2013-01-24 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
CN109212223B (zh) * 2012-05-18 2021-11-12 重症监护诊断股份有限公司 用于治疗或预报室性快速性心律失常事件风险的方法
CN102830234A (zh) * 2012-08-10 2012-12-19 杭州华得森生物技术有限公司 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒
DK2885641T3 (da) 2012-08-16 2018-01-29 Critical Care Diagnostics Inc Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension
CN104737170A (zh) * 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
RU2510505C1 (ru) * 2012-11-15 2014-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ определения вероятности выраженной сердечной недостаточности в клинической картине инфаркта миокарда
GB201310290D0 (en) * 2013-06-10 2013-07-24 Univ Manchester Method for determining a probability of a major adverse cardiac event (MACE)
CA2935958A1 (en) 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
ES2792227T3 (es) 2014-09-26 2020-11-10 Somalogic Inc Predicción de evento de riesgo cardiovascular y usos de la misma
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
WO2016140958A1 (en) * 2015-03-02 2016-09-09 Estes Edward Harvey Method and device to predict adverse cardiovascular events and mortality from an electrocardiogram-based validated risk score
CN109152529B (zh) * 2016-04-01 2021-10-22 心脏起搏器股份公司 多疾病患者管理
AT518560B1 (de) 2016-04-18 2018-01-15 Trumpf Maschinen Austria Gmbh & Co Kg Biegebalken für eine Schwenkbiegemaschine
CN110868911B (zh) 2017-04-29 2022-10-11 心脏起搏器股份公司 心力衰竭事件率评定
JP7057995B2 (ja) 2017-10-03 2022-04-21 株式会社国際電気通信基礎技術研究所 哺乳動物におけるうつ病の病態プロファイルを検出するバイオマーカーとその利用
US20200074313A1 (en) * 2018-08-29 2020-03-05 Koninklijke Philips N.V. Determining features to be included in a risk assessment instrument
JP7043374B2 (ja) 2018-09-18 2022-03-29 株式会社日立製作所 多機能神経フィードバックシステム及び多機能神経フィードバック方法
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US11551817B2 (en) 2020-01-14 2023-01-10 International Business Machines Corporation Assessing unreliability of clinical risk prediction
US20240288448A1 (en) * 2021-03-08 2024-08-29 Sanofi Cardiovascular Disease

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
US5217899A (en) 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
JP2665850B2 (ja) 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
JP2732005B2 (ja) 1992-12-14 1998-03-25 眞一 富永 ヒトｓｔ２をコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
JPH0731479A (ja) 1993-02-23 1995-02-03 Shinichi Tominaga マウスｓｔ２ｌをコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
WO1998007754A1 (en) 1996-08-23 1998-02-26 Human Genome Sciences, Inc. T1 receptor-like ligand ii
JP2001513641A (ja) 1997-02-28 2001-09-04 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｔ１／ｓｔ２−レセプターリガンド▲ｉｉｉ▼
DE19711932A1 (de) 1997-03-21 1998-09-24 Anne Katrin Dr Werenskiold In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms
ES2374621T3 (es) 1997-04-02 2012-02-20 The Brigham And Women's Hospital, Inc. Medios para evaluar el perfil de riesgo de un individuo de sufrir una enfermedad ateroesclerótica.
CA2293718A1 (en) 1997-06-10 1998-12-17 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
WO1999013331A1 (fr) 1997-09-11 1999-03-18 Shionogi & Co., Ltd. Procede de dosage immunologique pour bnp
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
GB9827348D0 (en) * 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
EP1140137A2 (en) 1998-12-18 2001-10-10 Scios Inc. Method for detection and use of differentially expressed genes in disease states
AU5309600A (en) 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
FR2795823B1 (fr) 1999-07-01 2001-11-23 Inst Nat Sante Rech Med Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
WO2001013900A2 (en) 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001070817A1 (fr) 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant
FR2807170B1 (fr) 2000-03-30 2002-06-28 Sipal Charniere elastique a frottement reduit
JP2004506443A (ja) 2000-08-22 2004-03-04 ブライハム　アンド　ウィメンズ　ホスピタル　インコーポレーテッド 心血管状態の診断および処置
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US6537221B2 (en) 2000-12-07 2003-03-25 Koninklijke Philips Electronics, N.V. Strain rate analysis in ultrasonic diagnostic images
FI20010019A (fi) 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
WO2002089657A2 (en) 2001-05-04 2002-11-14 Biosite, Inc. Diagnostic markers of acute coronary syndromes and methods of use thereof
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
EP3072978B1 (en) 2002-05-09 2018-07-11 The Brigham and Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker
WO2003100000A2 (en) 2002-05-24 2003-12-04 Tularik Inc. Amplification and overexpression of oncogenes
US8263325B2 (en) 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
US20040265926A1 (en) * 2002-11-21 2004-12-30 Leong Ng Bodily fluid markers of tissue hypoxia
WO2004056868A2 (en) 2002-12-19 2004-07-08 Endocube Sas Nf-hev compositions and methods of use
US20040133079A1 (en) 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
US20040220155A1 (en) 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20050123451A1 (en) 2003-10-31 2005-06-09 Hiroshi Nomura System and apparatus for body fluid analysis using surface-textured optical materials
CA3048093A1 (en) 2003-11-26 2005-06-23 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
ATE546734T1 (de) 2003-12-05 2012-03-15 Cleveland Clinic Foundation Risikomarker für eine herzkreislaufkrankheit
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja) 2004-03-31 2005-10-20 Akira Matsumori 心疾患の検査法
EP1833766A1 (en) 2004-12-17 2007-09-19 Clearwater Systems Corp. Method and apparatus for treating fluids
ES2388795T3 (es) 2005-01-24 2012-10-18 F. Hoffmann-La Roche Ag Utilización de péptidos de tipo Bnp para la evaluación del riesgo de sufrir insuficiencia cardiaca como consecuencia de la sobrecarga de volumen
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
US20070021977A1 (en) 2005-07-19 2007-01-25 Witt Biomedical Corporation Automated system for capturing and archiving information to verify medical necessity of performing medical procedure
JP4820192B2 (ja) 2006-03-17 2011-11-24 一般財団法人化学及血清療法研究所 急性冠症候群でのａｄａｍｔｓ１３の測定と利用
ES2351623T3 (es) * 2006-04-24 2011-02-08 Critical Care Diagnostics, Inc. Predicción de la mortalidad y detección de una enfermedad grave.
US20090305265A1 (en) 2006-04-27 2009-12-10 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
PT2021796E (pt) 2006-05-01 2012-04-19 Critical Care Diagnostics Inc Diagnóstico de doença cardiovascular
HUE025058T2 (hu) 2006-05-02 2016-01-28 Critical Care Diagnostics Inc Pulmonáris és cardiovasculáris betegség differenciáldiagnózisa
WO2007130627A2 (en) 2006-05-04 2007-11-15 The Brigham And Women's Hospital, Inc. Il-33 in the treatment and diagnosis of diseases and disorders
US20080057590A1 (en) * 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
RU2312591C1 (ru) 2006-06-14 2007-12-20 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией
WO2008116083A1 (en) 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
US20090111708A1 (en) 2007-05-11 2009-04-30 Seddon Johanna M Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
GB0713404D0 (en) 2007-07-11 2007-08-22 Integra Sp Ipr Ltd Altio graph
WO2009040133A1 (en) 2007-09-26 2009-04-02 Universitätsklinikum Heidelberg Osteopontin as novel prognostic biomarker for heart failure
FR2923029B1 (fr) 2007-10-26 2009-11-20 Minima Lunettes de type sans entourage a branches filaires
DK2827152T3 (en) 2008-04-18 2016-09-12 Critical Care Diagnostics Inc PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS
WO2010025393A2 (en) * 2008-08-28 2010-03-04 The Regents Of The University Of California Protein biomarkers and methods for diagnosing kawasaki disease
WO2010054810A1 (en) 2008-11-11 2010-05-20 B.R.A.H.M.S Ag Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
CN102812359A (zh) 2009-11-13 2012-12-05 Bg医药公司 心肌梗死的风险因子和预测
US8258456B2 (en) 2009-11-27 2012-09-04 Himax Imaging, Inc. Image sensor
BR112012025728B1 (pt) 2010-04-09 2022-01-11 Critical Care Diagnostics, Inc Anticorpos isolados ou fragmentos que se liga a st2 humano solúvel, hibridoma, kit, bem como métodos para quantificação de um nível de st2 solúvel humano em uma amostra de um indivíduo, e para a predição do risco de morte dentro de um ano em um indivíduo
CN103328976B (zh) 2010-11-01 2016-08-10 B.R.A.H.M.S有限公司 具有非特定主诉的患者的预后和风险评估
RU2452394C1 (ru) 2010-11-09 2012-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
EP3605104B1 (en) 2011-03-17 2021-09-15 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
US8615387B2 (en) * 2011-04-07 2013-12-24 Invensys Systems, Inc. Dynamic simulation of fluid filled vessels
WO2013012945A1 (en) 2011-07-18 2013-01-24 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
CN109212223B (zh) 2012-05-18 2021-11-12 重症监护诊断股份有限公司 用于治疗或预报室性快速性心律失常事件风险的方法
DK2885641T3 (da) * 2012-08-16 2018-01-29 Critical Care Diagnostics Inc Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension
CN104737170A (zh) * 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
US9665593B2 (en) * 2013-03-28 2017-05-30 International Business Machines Corporation Dynamically synching elements in file
JP6178687B2 (ja) 2013-09-27 2017-08-09 富士機械工業株式会社 グラビア塗工装置
CA2935958A1 (en) 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
US9934249B2 (en) 2014-06-03 2018-04-03 Conduent Business Machines Services, Llc Systems and methods for context-aware and personalized access to visualizations of road events
USD800333S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800332S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
HUE039963T2 (hu) 2019-02-28
SI2269063T1 (sl) 2014-01-31
EP2269063B1 (en) 2013-08-21
US20090264779A1 (en) 2009-10-22
HK1152750A1 (en) 2012-03-09
PL2660599T3 (pl) 2015-03-31
JP2011520098A (ja) 2011-07-14
JP6484679B2 (ja) 2019-03-13
EP2827152A1 (en) 2015-01-21
US9886553B2 (en) 2018-02-06
EP2269063A2 (en) 2011-01-05
ES2590213T3 (es) 2016-11-18
EP3093663B1 (en) 2018-06-13
JP2014178322A (ja) 2014-09-25
SI3093663T1 (sl) 2018-10-30
DK3093663T3 (en) 2018-09-24
EP2660599A1 (en) 2013-11-06
DK2660599T3 (en) 2014-12-08
WO2009129454A2 (en) 2009-10-22
AU2009236109A1 (en) 2009-10-22
HK1185658A1 (en) 2014-02-21
JP2016048272A (ja) 2016-04-07
PT2660599E (pt) 2014-11-28
AU2016200697A1 (en) 2016-02-25
AU2009236109B2 (en) 2015-11-05
EP3093663A1 (en) 2016-11-16
HRP20141056T1 (hr) 2015-01-02
JP2017203784A (ja) 2017-11-16
AU2016200697B2 (en) 2018-01-04
EP2269063A4 (en) 2011-05-04
SI2827152T1 (sl) 2016-10-28
DK2827152T3 (en) 2016-09-12
SI2660599T1 (sl) 2014-12-31
JP5873521B2 (ja) 2016-03-01
US20130244236A1 (en) 2013-09-19
HRP20131100T1 (hr) 2014-01-31
US11170896B2 (en) 2021-11-09
ES2687401T3 (es) 2018-10-25
AU2018202350A1 (en) 2018-04-26
JP2019105645A (ja) 2019-06-27
US9965593B2 (en) 2018-05-08
US8090562B2 (en) 2012-01-03
US20120065897A1 (en) 2012-03-15
PL3093663T3 (pl) 2018-11-30
JP5526122B2 (ja) 2014-06-18
JP2021039108A (ja) 2021-03-11
EP3378955A1 (en) 2018-09-26
US20150081224A1 (en) 2015-03-19
PL2827152T3 (pl) 2016-12-30
EP2827152B1 (en) 2016-06-08
ES2525029T3 (es) 2014-12-16
PT2827152T (pt) 2016-09-13
PT3093663T (pt) 2018-10-19
PL2269063T3 (pl) 2014-04-30
ES2443125T3 (es) 2014-02-17
WO2009129454A3 (en) 2010-01-28
EP2660599B1 (en) 2014-09-10
DK2269063T3 (da) 2013-12-02
CA2720674A1 (en) 2009-10-22
HK1206419A1 (en) 2016-01-08
JP6788050B2 (ja) 2020-11-18
US20180233229A1 (en) 2018-08-16
JP6200975B2 (ja) 2017-09-20
PT2269063E (pt) 2013-11-27

Similar Documents

Publication Publication Date Title
US11170896B2 (en) Predicting risk of major adverse cardiac events
US11016103B2 (en) Predicting mortality and detecting severe disease
AU2016200419B2 (en) Predicting mortality and detecting severe disease